Literature DB >> 7962044

Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Y Kuwashima1, T Uehara, K Kishi, K Shiromizu, M Matsuzawa, S Takayama.   

Abstract

Immunohistochemical characteristics of undifferentiated carcinomas of the ovary were examined using formalin-fixed, paraffin-embedded tissues with an avidin-biotin staining approach. Eight cases were collected from the pathology files of our Institute from a total of 214 recorded malignant ovarian tumors. For immunostaining, antibodies reacting with epithelial membrane antigen (EMA), pankeratin, vimentin, CA 125, CA 19-9, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), alpha-1-antitrypsin (AT), epidermal growth factor receptor (EGFR), c-erbB-2, bcl-2 and p53 proteins were used. All the cases examined were positive for EMA and pankeratin, specific markers for epithelial tumors, negative for the non-epithelial tumor marker, vimentin, and also positive for EGFR. Interestingly, only one case was positive for CA 125, despite it being one of the commonest reported indicators of ovarian cancer. CA 19-9 was positive in 7 cases, CEA in 5, AFP in 2, AT in 6 and c-erbB-2 protein in 4. Two cases were positive for p53 protein, and in 1 of these positive staining for bcl-2 was also observed. These results indicate that the epithelial nature is well preserved in undifferentiated ovarian carcinomas, although consistently positive reactions were not observed within the cases for some antigens. They further clearly show that a negative signal for CA 125 can not be considered to exclude the possibility of a primary ovarian tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962044     DOI: 10.1007/BF01245380

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  40 in total

Review 1.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases.

Authors:  T S Loy; J T Quesenberry; S C Sharp
Journal:  Am J Clin Pathol       Date:  1992-08       Impact factor: 2.493

4.  Immunohistochemistry of gastric carcinomas and associated diseases: novel distribution of carcinoembryonic antigen and secretory component on the surface of gastric cancer cells.

Authors:  H Nagura; Y Tsutsumi; Y Shioda; K Watanabe
Journal:  J Histochem Cytochem       Date:  1983-01       Impact factor: 2.479

5.  Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.

Authors:  D P Wang; I Konishi; M Koshiyama; Y Nanbu; T Iwai; H Nonogaki; T Mori; S Fujii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

7.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

Authors:  A Berchuck; G C Rodriguez; A Kamel; R K Dodge; J T Soper; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-02       Impact factor: 8.661

8.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

10.  Immunohistochemical type distinction of alpha-fetoprotein in various alpha-fetoprotein-secreting tumors.

Authors:  T Okamoto; K Hirabayashi; T Ishiguro
Journal:  Jpn J Cancer Res       Date:  1993-04
View more
  5 in total

Review 1.  Ovarian Sertoli-Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature review.

Authors:  Mariana Horta; Teresa Margarida Cunha; Rita Canas Marques; Ana Félix
Journal:  J Radiol Case Rep       Date:  2014-11-30

2.  Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.

Authors:  H J Schneider; S A Sampson; D Cunningham; A R Norman; H J Andreyev; J V Tilsed; P A Clarke
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 3.  Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.

Authors:  Simona D'Aguanno; Donatella Del Bufalo
Journal:  Cells       Date:  2020-05-21       Impact factor: 6.600

4.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

Review 5.  Targeting BCL2-Proteins for the Treatment of Solid Tumours.

Authors:  Meike Vogler
Journal:  Adv Med       Date:  2014-08-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.